We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.30 | 1.20 | 1.40 | 1.30 | 1.30 | 1.30 | 333,263 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.71 | 1.76M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/2/2018 10:01 | Crazy init, why would they do that as part of their job! Must be scan artists! Lol | margic | |
12/2/2018 09:45 | as has been said PWhite73, your posts are full of suposition and conjecture and your post above is a prime example. mm's tinker with the price and the spread on all stocks, it's not unusual, that's how they create a market, that's their job and that's why they are called mm's. Please just try and post facts. | minja19 | |
12/2/2018 09:42 | Worth mentioning also, that 8 ema has brought in buyers, a close above the 50 dma would be good and looks achievable today. | minja19 | |
12/2/2018 09:17 | Ex Founder of Physiomics (PYC) Peter Hoskins who writes on ADVFN as "ant15" ant15 - 30 Nov 2017 - 15:07:26 - 3710 of 4892 Writing as a Founder of Physiomics I am a shareholder but do not represent the company in any capacity. WHY THIS SHARE IS WORTH A £1.00 giving it a market cap of still less than £60.million *It is first to market *Scarcity of trained personnel in what is still an emergent technology ( there are currently over a 1000 vacancies to be filled in this sector and few trained personnel ) *The development time needed to populate models and most importantly the availability of patient data that needs to be accessed apart from what is available in the literature is protracted PYC has been through this curve perfecting its models over time. * The Biometric Grant serves to demonstrate not only the faith in the company but also underpins the access PYC is being given to Patient data In this case in the field of Oesophgeal Cancer *Collaborations with major pharmas have been constrained whilst the models are perfected and due to the secretive nature of all pharmas who generally speaking do not want to share data. The latest contract has dramatically increased the visibility of what PYC do and do best and will encourage a raft of Biotech analysts to write it up as more contracts are announced *PYC's Cardiac Toxicity Model is 50% plus better than any other available on the market Why is this important? it is the major cause of attrition in clinical trials ( drug failure ) *The cost savings PYC is able to realise for major Pharma is key and further to small Biotechnology companies whose funding is limited as they try to move molecules into clinical trials. * Big Pharmas feed their development pipelines by acquiring or licensing in small bio's however these sales have moved progressively from Targets 20 years ago to IND candidates and onto Phase 1/2 putting the burden of proof onto the small Bio Techs who need to conserve and raise cash ( not easy and never has been ) *In 2010 Scientific American stated the cost of Development of a drug from start to finish FDA approval was $1.4 billion...In 2016 Association of British Pharmaceutical Industry Has upped this to £1.5 billion ( sterling) a really significant increase. NOTING that only 1 in 5000 drugs get final approval and this is not factored into the costs as above as representing only a successful transition of 1 drug to approval *In America alone $12-%14 billion per year is spent on Animal Testing Robert Solari a senior research fellow at Imperial College states "The predictive power of biology in reseach is relatively poor in research labs" and notes that the efficacy of animal testing are not particulary predictive of Human Efficacy PYC is "in Silico" ( in computer) its accuracy is one of its major plus points * PYC is striving to personalised medicine The HOLY GRAIL with tremendous Social and Financial Implications. * Sooner rather than later The FDA in America will have to recognise that rational drugs designed in computers can be tested in them too saving countless millions of development costs and most importantly time taken to approval ie move from the 20 to the 21st century * PYC has taken time to develop its excellent technology I believe I have cited the reasons for its true value. It has been challenged in recent times but has now become of age an is exceptionally well positioned in a market sector that is set to expand exponentially. To recap A leading British Technology currently way undervalued and one that is not a speculative BUY It has proven technology in a burgeoning sector and might well become the focus of an acquisition target as it is still so undervalued | the stigologist | |
12/2/2018 09:06 | The MM tinker with the price all the time trying to give mug PIs the illusion of recovery and the dizzy heights of 32p are on the way back. They are not. Things have not changed here. If it hadn't been for the November 2017 frenzy I do believe they would have thrown in the towel as far as the listing is concerned. They don't need it. They are a well run company and can survive just on the collaborative research work with the pharmas. | pwhite73 | |
12/2/2018 08:55 | It's probably more about product take up that validates said product.....just my take.. | bobdown2 | |
12/2/2018 08:53 | Ok looks like I made a mistake not buying in here on Friday at 7.9p! At least short-term. But I was concerned about a possible fund-raise and PWhite's warnings about patents do seem concern-inducing. I don't know much about oncology so am being cautious. Even if I miss out on a chance to make money this is a chance to learn. Stig when was the Sareum payment & how much was it? | runthejoules | |
12/2/2018 08:39 | 50-100p target should be starting point CancerDSS tool could help break US healthcare market and then its global and stellar would not rule out £10 | the stigologist | |
12/2/2018 08:38 | Moved up a bit more....worth another mention ??? | bobdown2 | |
12/2/2018 08:33 | Moving up nicely today....just thought I would mention it... | bobdown2 | |
11/2/2018 15:18 | And it's Dr not Mr Millen. | patientcapital | |
11/2/2018 13:00 | Dr Jim Millen, CEO said: "We believe that the signing of agreements with three major pharmaceutical clients within the space of three months is a real sign of the confidence in our technology that is starting to build within the industry. Our aim now will be to develop longer-term relationships with these major companies and to secure further pre-clinical and clinical projects." So they've got their foot in the door with 3 Major Pharmas out of a client list of 58 And they've only just started rolling it out within those clients Merck went from £30k deals to €500k deals Why shouldn't Glaxo or whoever else also go from £30-70k initial deals to £500+k ? I think recent Industry and Regulatory approvals and validation of In Silico Clinical Trials (aka Biosimulation aka 'Modelling and Simulation') is causing a domino effect and Physiomics are going to be HUGE beneficiaries of this perfect storm. In the last few weeks 3 Major Pharmas have signed up for c.£600k of Services from Physiomics It is a quite clear step change/tipping point in the revenues of Physiomics and with the limited overheads they must be close to profitability now. | the stigologist | |
11/2/2018 10:23 | Anyway onto a more serious subject I addressed the issue in my post 1575 of the patents for Systemcell expiring in 2022 in the US and already expired in 2016 in Europe. Systemcell technology is the software that PYC Virtual Tumour Technology is based on. I suggested this is the main reason why a major pharma would not pay £200m for PYC. Technology patents expire after 20 years. It effects all companies including Microsoft, Apple and Samsung. The reason why these companies continue to thrive is due to their brand name and the filing of new patents. Comparisons have been drawn between the undervalued market cap of PYC and Oxford Biodynamics (OBD) this is an error. OBD is a much larger company it only listed in December 2016 the IPO raised £20 million. It has been on the market for less than two years unlike PYC's 15 years. OBD's main technology is called EpiSwitch. The technology was granted a US patent and trademark protection on 03/10/2017. PYC's was granted in 2002 and to the best of my knowledge they have not filed any other patents. | pwhite73 | |
11/2/2018 10:18 | Ex Founder of Physiomics (PYC) Peter Hoskins who writes on ADVFN as "ant15" ant15 - 30 Nov 2017 - 15:07:26 - 3710 of 4892 Writing as a Founder of Physiomics I am a shareholder but do not represent the company in any capacity. WHY THIS SHARE IS WORTH A £1.00 giving it a market cap of still less than £60.million *It is first to market *Scarcity of trained personnel in what is still an emergent technology ( there are currently over a 1000 vacancies to be filled in this sector and few trained personnel ) *The development time needed to populate models and most importantly the availability of patient data that needs to be accessed apart from what is available in the literature is protracted PYC has been through this curve perfecting its models over time. * The Biometric Grant serves to demonstrate not only the faith in the company but also underpins the access PYC is being given to Patient data In this case in the field of Oesophgeal Cancer *Collaborations with major pharmas have been constrained whilst the models are perfected and due to the secretive nature of all pharmas who generally speaking do not want to share data. The latest contract has dramatically increased the visibility of what PYC do and do best and will encourage a raft of Biotech analysts to write it up as more contracts are announced *PYC's Cardiac Toxicity Model is 50% plus better than any other available on the market Why is this important? it is the major cause of attrition in clinical trials ( drug failure ) *The cost savings PYC is able to realise for major Pharma is key and further to small Biotechnology companies whose funding is limited as they try to move molecules into clinical trials. * Big Pharmas feed their development pipelines by acquiring or licensing in small bio's however these sales have moved progressively from Targets 20 years ago to IND candidates and onto Phase 1/2 putting the burden of proof onto the small Bio Techs who need to conserve and raise cash ( not easy and never has been ) *In 2010 Scientific American stated the cost of Development of a drug from start to finish FDA approval was $1.4 billion...In 2016 Association of British Pharmaceutical Industry Has upped this to £1.5 billion ( sterling) a really significant increase. NOTING that only 1 in 5000 drugs get final approval and this is not factored into the costs as above as representing only a successful transition of 1 drug to approval *In America alone $12-%14 billion per year is spent on Animal Testing Robert Solari a senior research fellow at Imperial College states "The predictive power of biology in reseach is relatively poor in research labs" and notes that the efficacy of animal testing are not particulary predictive of Human Efficacy PYC is "in Silico" ( in computer) its accuracy is one of its major plus points * PYC is striving to personalised medicine The HOLY GRAIL with tremendous Social and Financial Implications. * Sooner rather than later The FDA in America will have to recognise that rational drugs designed in computers can be tested in them too saving countless millions of development costs and most importantly time taken to approval ie move from the 20 to the 21st century * PYC has taken time to develop its excellent technology I believe I have cited the reasons for its true value. It has been challenged in recent times but has now become of age an is exceptionally well positioned in a market sector that is set to expand exponentially. To recap A leading British Technology currently way undervalued and one that is not a speculative BUY It has proven technology in a burgeoning sector and might well become the focus of an acquisition target as it is still so undervalued | the stigologist |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions